Literature DB >> 9394027

Metabolism of clozapine by cDNA-expressed human cytochrome P450 enzymes.

K Linnet1, O V Olesen.   

Abstract

The metabolism of clozapine was studied in vitro using cDNA-expressed human cytochrome P450 (CYP) enzymes 1A2, 3A4, 2C9, 2C19, 2D6, and 2E1. CYP1A2, 3A4, 2C9, 2C19, and 2D6 were able to N-demethylate clozapine. N-Oxide formation was exclusively catalyzed by CYP3A4. CYP2E1 did not metabolize clozapine. With regard to quantitative relationships, CYP1A2, 2C9, 2C19, and 2D6 displayed KM values ranging from 13 to 25 microM, whereas CYP3A4 had a 5-10 times higher KM value. CYP2C19 and 2D6 had the highest Vmax values (149-366 mol/hr/mol CYP). Taking into account the typical relative distribution of amounts of CYP enzymes in the liver, a simulation study suggested that at therapeutic concentrations CYP2C19 and CYP3A4 each accounted for about 35% of the metabolism. At toxic concentrations, the relative importance of CYP3A4 increased.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9394027

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  11 in total

1.  Identification of the human cytochrome P450 isoforms mediating in vitro N-dealkylation of perphenazine.

Authors:  O V Olesen; K Linnet
Journal:  Br J Clin Pharmacol       Date:  2000-12       Impact factor: 4.335

Review 2.  Pharmacokinetic factors in the adverse cardiovascular effects of antipsychotic drugs.

Authors:  Candace S Brown; Richard G Farmer; Judith E Soberman; Samantha F Eichner
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 3.  Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

Authors:  K Venkatakrishnan; L L von Moltke; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2000-02       Impact factor: 6.447

Review 4.  Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance.

Authors:  Eveline Jaquenoud Sirot; Jan Willem van der Velden; Katharina Rentsch; Chin B Eap; Pierre Baumann
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 5.  Interactions between the cytochrome P450 system and the second-generation antipsychotics.

Authors:  Trevor I Prior; Glen B Baker
Journal:  J Psychiatry Neurosci       Date:  2003-03       Impact factor: 6.186

Review 6.  Metabolism, pharmacogenetics, and metabolic drug-drug interactions of antipsychotic drugs.

Authors:  J Fang; J W Gorrod
Journal:  Cell Mol Neurobiol       Date:  1999-08       Impact factor: 5.046

7.  Pharmacokinetics of clozapine and its metabolites in psychiatric patients: plasma protein binding and renal clearance.

Authors:  G Schaber; I Stevens; H J Gaertner; K Dietz; U Breyer-Pfaff
Journal:  Br J Clin Pharmacol       Date:  1998-11       Impact factor: 4.335

Review 8.  Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing?

Authors:  Marja-Liisa Dahl
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

9.  The Value of Desmethylclozapine and Serum CRP in Clozapine Toxicity: A Case Report.

Authors:  Khalid Abou Farha; Andre van Vliet; Henderikus Knegtering; Richard Bruggeman
Journal:  Case Rep Psychiatry       Date:  2012-08-15

10.  Potential Role of Patients' CYP3A-Status in Clozapine Pharmacokinetics.

Authors:  Katalin Tóth; Gábor Csukly; Dávid Sirok; Ales Belic; Ádám Kiss; Edit Háfra; Máté Déri; Ádám Menus; István Bitter; Katalin Monostory
Journal:  Int J Neuropsychopharmacol       Date:  2017-07-01       Impact factor: 5.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.